drugset / Trial / NCT04235101
Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
SYD985.004 is a two-part phase I study with the antibody-drug conjugate SYD985 in combination with niraparib aimed at evaluating safety, pharmacokinetics and efficacy in patients with HER2-expressing locally advanced or metastatic solid tumours.
Timeline
- Start
- 2020-06-22
- Primary completion
- 2023-04-24
- Completion
- 2023-04-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niraparib | Small molecule | 100 mg | Oral |
| Subject | Niraparib | Small molecule | 200 mg | Oral |
| Subject | Niraparib | Small molecule | 300 mg | Oral |
| Subject | Trastuzumab duocarmazine | Other / unclassified | — | Intravenous |